Keywords: Corticosteroids, HMGB1, ACE inhibitors, hydroxychloroquine, statins, vitamin D.
[1]
Villar , et al. Dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8(3): 267-76.
[http://dx.doi.org/10.1016/S2213-2600(19)30417-5]
[http://dx.doi.org/10.1016/S2213-2600(19)30417-5]
[2]
Horby , et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384(8): 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436]
[http://dx.doi.org/10.1056/NEJMoa2021436]
[3]
Tomazini , et al. COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324(13): 1307-16.
[http://dx.doi.org/10.1001/jama.2020.17021]
[http://dx.doi.org/10.1001/jama.2020.17021]
[4]
Sterne , et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324(13): 1330-41.
[http://dx.doi.org/10.1001/jama.2020.17023]
[http://dx.doi.org/10.1001/jama.2020.17023]
[5]
Hoertel , et al. AP-HP/Université de Paris/INSERM Covid-19 research collaboration and AP-HP Covid CDR Initiative. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study. Br J Clin Pharmacol 2021.
[http://dx.doi.org/10.1111/bcp.14784]
[http://dx.doi.org/10.1111/bcp.14784]
[6]
Águas , et al. CoMo Consortium. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun 2021; 12(1): 915. doi: 10.1038/s41467-021-21134-2. Erratum in: Nat Commun. 2021; 12(1): 1596.
[http://dx.doi.org/10.1038/s41467-021-21134-2]
[http://dx.doi.org/10.1038/s41467-021-21134-2]
[7]
Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: A therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med 2020; 26(1): 42.
[http://dx.doi.org/10.1186/s10020-020-00172-4]
[http://dx.doi.org/10.1186/s10020-020-00172-4]
[8]
Geröet al , et al. Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening. PLoS One 2013 Jun 14;8; (6): e65994
[http://dx.doi.org/10.1371/journal.pone.0065994]
[http://dx.doi.org/10.1371/journal.pone.0065994]
[9]
Wu , et al. Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. Proc Natl Acad Sci USA 2020; 117(45): 28336-43.
[http://dx.doi.org/10.1073/pnas.2018030117]
[http://dx.doi.org/10.1073/pnas.2018030117]
[10]
Wei , et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell 2021; 184(1): 76-91.e13.
[http://dx.doi.org/10.1016/j.cell.2020.10.028]
[http://dx.doi.org/10.1016/j.cell.2020.10.028]
Article Metrics
